Praxis für Psychotherapie und Supervision Claus Roeske Aufmerksamkeits- und Konzentrationsstörungen Terminologie Es gibt eine Reihe von Störungen und Erkrankungen, die als Symptome Defizite bei der Aufmerksamkeit, der Konzentration oder der Impulskontrolle haben. Nur wenn es sich dabei um die primäre Problematik handelt spricht man von ADS oder ADHS. Dies sind die gängige Abkürzung und bedeutet „Aufmerksamkeitsdefizit Störung". Das H steht für „Hyperaktivität". Die Störungen der Aufmerksamkeit und Impulskontrol e kann mit und ohne Hyperaktivität vorkommen. Eine weitere gebräuchliche Abkürzung ist HKS, dies bedeutet „hyperkinetisches Syndrom". Manchmal findet man auch den Begriff Zappelphillipsyndrom. Früher verwendet man auch den Begriff „MCD" (minimale cerebrale Dysfunktion). Dies war ein unspezifischer Sammelbegriff, der für al e möglichen Funktionsstörungen verwandt wurde, bei denen man vermutete, dass eine hirnorganische Ursache existieren könnte. Klassifikation Im ICD-10 Klassifikationssystem gehört AD(H)S zu den „Verhaltens- und emotionalen Störungen mit Beginn der Kindheit und Jugend". Im Kapitel F 90 werden die „hyperkinetischen Störungen" zusammengefasst. Hyperkinese bedeutet „übermäßige Aktivität, Unruhe in den Bewegungen mit Muskelzuckungen und unwil kürlichen Bewegungen des Körpers und der Gliedmaßen". (www.duden.de ) „ Diese Gruppe von Störungen ist charakterisiert durch einen frühen Beginn, meist in den ersten fünf Lebensjahren, einen Mangel an Ausdauer bei Beschäftigungen, die kognitiven Einsatz verlangen, und eine Tendenz, von einer Tätigkeit zu einer anderen zu wechseln, ohne etwas zu Ende zu bringen; hinzu kommt eine desorganisierte, mangelhaft regulierte und überschießende Aktivität. Verschiedene andere Auffäl igkeiten können zusätzlich vorliegen. Hyperkinetische Kinder sind oft achtlos und impulsiv, neigen zu Unfällen und werden oft bestraft, weil sie eher aus Unachtsamkeit als vorsätzlich Regeln verletzen. Ihre Beziehung zu Erwachsenen ist oft von einer Distanzstörung und einem Mangel an normaler Vorsicht und Zurückhaltung geprägt. Bei anderen Kindern sind sie unbeliebt und können isoliert sein. Beeinträchtigung kognitiver Funktionen ist häufig, spezifische Verzögerungen der motorischen und sprachlichen Entwicklung kommen überproportional oft vor. Sekundäre Komplikationen sind dissoziales Verhalten und niedriges Selbstwertgefühl." (ICD – 10 ) Weiter wird differenziert zwischen F 90.0 „Einfache Aktivitäts- und Aufmerksamkeitsstörung" F 90.1 „Hyperkinetische Störung des Sozialverhaltens" und zwei weiteren „Restkategorien" bei diagnostischer Unsicherheit (F90.8 und F90.9) F 90.1 wird kodiert, wenn zu den Symptomen einer ADHS auch Störungen des Sozialverhaltens gezeigt werden. Wenn eine Konzentrations- und Aufmerksamkeitsstörung ohne die Symptomatik der Hyperaktivität vorliegt spricht man von ADS. Die passende Kategorie im ICD-10 wäre: F98.8 Sonstige näher bezeichnete Verhaltens- und emotionale Störungen mit Beginn in der Kindheit und Jugend darunter auch Aufmerksamkeitsstörung ohne Hyperaktivität Die Klassifikation des ADS ist derzeit unzureichend. ADS befindest sich in einer Restekategorie mit Symptomatiken wie Daumenlutschen, Exzessiver Masturbation , Nägelkauen, Nasebohren. Wie wird AD(H)S diagnostiziert? Es gibt derzeit keinen Test oder ein anderes medizinische Untersuchungsmethoden, die ADHS sicher beweisen könnte. Die „Diagnose" ist lediglich das Ergebnis eines narrativen Prozesses der Betroffenen und deren Bezugspersonen, einer Verhaltensbeobachtung oder eine messbare Normvariante bei standardisierten Konzentrations- oder Aufmerksamkeitstest.
UntitledOvarian reserve in women with primary antiphospholipid syndrome LYS Yamakami1, PC Serafini1, DB de Araujo2,3, E Bonfa´2, EP Leon2, EC Baracat1 and CA Silva2,4 1Department of Gynecology; 2Division of Rheumatology; 3Department of Rheumatology, Hospital do Servidor Pu´blico Estadual de Sa˜o Paulo, Sa˜o Paulo, Brazil; and 4Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil Objective: The objective of this paper is to evaluate ovarian reserve in primary antiphospho-lipid syndrome (PAPS) women and the association between ovarian reserve tests and clinicaland laboratorial parameters, and anti-corpus luteum antibody (anti-CoL). Methods: Wescreened 85 female patients between 18 to 40 years old with APS. Of these, 67 patients wereexcluded because of association with other autoimmune diseases (n ¼ 42), contraindication orunwillingness to stop hormonal contraceptive (n ¼ 21), current pregnancy or breastfeeding(n ¼ 3) and previous ovarian surgery (n ¼ 1). Therefore, a cross-sectional study was conductedin 18 PAPS patients and 24 healthy women. They were evaluated at early follicular phase withmeasurement of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, andanti-Mu¨llerian hormone (AMH) and sonographic antral follicle count (AFC). Serum meas-urement of anti-CoL was determined by immunoblot analysis. All analyses were performedafter at least six months from the last intake of hormonal contraceptive and resumption ofmenstruation. Results: The mean age was comparable in PAPS and controls (33.0 5.0 vs.
30.4 7.0 years; p ¼ 0.19). Regarding ovarian reserve tests, the frequencies of low AFC (10)(56% vs. 22%, p ¼ 0.04) and very low AFC (5) (37% vs. 9%, p ¼ 0.04) were significantlyhigher in PAPS patients than controls. Trends of higher frequencies of reduced (<1.0 ng/ml),low patients (p ¼ 0.08, p ¼ 0.07 and p ¼ 0.07, respectively). FSH, LH and estradiol were similarin patients and controls. There was no association between low ovarian reserve and specifictypes of antiphospholipid antibodies. Anti-CoL was solely observed in PAPS patients (11%vs. 0%; p ¼ 0.177) and was not related to ovarian reserve tests. Conclusion: Women sufferingfrom PAPS possessed reduced ovarian reserve, with prevalence greater than 50%.
(2014) 23, 862–867.
Key words: Antiphospholipid syndrome; autoimmune diseases; anti-Mu¨llerian hormone;antral follicle count; ovarian reserve test they might have additional burdens on their repro-ductive health.1,2 Antiphospholipid syndrome (APS) is an auto- Likewise, it is known that aging, smoking and ovarian surgery decrease the quantity and quality either as an isolated condition known as primary of primordial follicles in the ovaries and, ultim- APS (PAPS) or in association with other auto- ately, the ovarian reserve (OR).3,4 Conditions immune diseases, particularly systemic lupus ery- such as autoimmune oophoritis,5,6 ovarian ische- thematosus (SLE).1 Females aﬄicted by PAPS mia7,8 and corpus luteum hemorrhage9 may lead have an increased risk of complications during to diminished OR. Females suﬀering from PAPS pregnancy, and studies have also implied that are susceptible to the above-mentioned complica-tions, yet the medical literature lacks informationon how this relevant autoimmune disease aﬀectsthe OR of these women.
Correspondence to: Clovis Artur Silva, Faculdade de Medicina da Accordingly, we assessed the OR proﬁle of USP, Reumatologia, Av Dr Arnaldo, 455, 3 andar, sala 3105, Sa˜o women suﬀering from PAPS by performing hormo- Paulo – SP – 01246-903, Brazil.
nal evaluations and state-of-the-art pelvic ultra- Email: [email protected] and CAS should be considered similar in author order.
sound scanning, and we compared these results Received 2 November 2013; accepted 6 March 2014 with the OR proﬁle of healthy women.
! The Author(s), 2014. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav Ovarian reserve in PAPSLYS Yamakami et al.
Materials and methods Demographic data, PAPS manifestations, andtreatment Patients and controls Each patient's medical records were carefully Eighty-ﬁve patients aged 18 to 40 years old with reviewed concerning clinical, immunological and treatment ﬁndings. PAPS manifestations were Outpatient Clinic of the Rheumatology Division deﬁned as vascular thrombosis (one or more clin- ical episodes of arterial, venous, or small-vessel Medicina da Universidade de Sa˜o Paulo and thrombosis in any tissue or organ) or pregnancy were invited to participate in this study. These morbidity (fetal death; premature birth before the patients were screened for PAPS during the 34th week of gestation because of eclampsia, period from April 2010 to March 2013. All severe pre-eclampsia, or placental insuﬃciency; patients had a previous history of thrombosis, or three or more consecutive spontaneous abor- and none were newly diagnosed. None had throm- tions).1 All patients were on long-term warfarin bosis at entry and all were on long-term use of treatment. Brazilian socio-economic stratiﬁcation warfarin. The median time of warfarin use was was carried out according to the Associac¸a˜o 5.05 years (0.7–12.9). Participants were excluded from the study if they were pregnant, breastfeed- Mercados criteria.10 Body mass index (BMI) was ing, unwilling to participate in the study, had med- deﬁned as the weight in kilograms/height in ical contraindications, possessed an increased risk meters2 (kg/m2).
of corpus luteum bleeding after stopping use ofprogestogen-only contraceptives,9 underwent pre- Gynecologic evaluation vious ovarian surgery, required systemic chemo- Complete history and physical examination includ- therapy, underwent pelvic radiotherapy, were ing history of the age at menarche and detailed currently using a long-acting gonadotropin release obstetric data were recorded.
hormone agonist (GnRH-a), presented with anadditional autoimmune disease, or had an end- stage renal disease. None of them were underestrogen contraceptive during the study or any- Blood samples were drawn by venipuncture in the time during their treatment.
early follicular phase (menstrual cycle day 2 Of the 85 women, 67 were excluded because of through 4). All sera were processed in a centrifuge an associated autoimmune condition (n ¼ 42), and stored at 70C until analysis. Follicle-stimu- contraindications or unwillingness to stop use of hormonal contraceptives (n ¼ 21), currently being 12.5 IU/l), luteinizing hormone (LH) (reference pregnant or breastfeeding (n ¼ 3), or because of level: 2.4–12.6 IU/l) and estradiol (E2) (reference previous ovarian surgery (n ¼ 1). Therefore, the level: 166 pg/ml) were measured by radioimmuno- assay using a commercial kit (CobasÕ, Roche, women with PAPS. The control group included Mannheim, Germany). Intra- and inter-assay coef- ﬁcients of variation were recommended by the recruited from the primary care clinic nearby our manufacturer and were limited to 5.7 and 3.6%, tertiary hospital. The control volunteers were sub- respectively. FSH concentrations were considered ject to the same inclusion and exclusion criteria.
elevated when the levels were equal to or greater All PAPS participants voluntarily agreed to dis- than 10 IU/l.4,11,12 continue the use of hormonal contraceptives Anti-Mu¨llerian hormone (AMH) was measured during a period of at least six months and had by enzyme-linked immunosorbent assay (ELISA) at least two consecutive menstruations to reveal in duplicated samples (AMH Gen II ELISA, the onset of normal endocrinological hypothala- Beckman Coulter Inc, Brea, CA, USA). Intra- mic-pituitary-ovarian axis activity. None of our and interassay coeﬃcients of variation were limited PAPS patients and controls had hypergonado- to 5.4% and 5.6%, respectively. AMH levels were trophic amenorrhea, which would suggest primary classiﬁed by cutoﬀ values: lower than 1.0 ng/ml ovarian insuﬃciency (high levels of FSH >40 IU/l (reduced), lower than 0.5 ng/ml (low) and lower and sustained amenorrhea).9 The local ethics com- than 0.2 ng/ml (negligible).13,14 mittee of our university hospital approved this Transvaginal ultrasound was carried out to study, and informed consent was obtained from determine the antral follicle count (AFC) and all participants.
the mean ovarian volume on the same day that Ovarian reserve in PAPS LYS Yamakami et al.
the blood was drawn. Transvaginal ultrasound Statistical analysis was not performed in women not engaged in Results are shown as the mean standard devi- ation (SD) or median (range) for continuous vari- were performed by an experienced, trained, repro- ables and as percentages for categorical variables.
ductive specialist (LYSY) using a 6.5 MHz endo- For continuous variables, data were compared by vaginal transducer (HD3, Philips Ultrasound, the t test and Mann-Whitney test to evaluate dif- Bothell, WA, USA) who was blinded to the vol- ferences between the PAPS group and control unteers' diagnoses and blood test results. Ovaries group. For categorical variables, diﬀerences were were scanned in axial and longitudinal planes, and assessed by Fisher's exact test. The level of signiﬁ- at least two measurements of length (L), width cance was set at 5% (p < 0.05).
(W) and thickness (T) were obtained and used tocalculate mean ovarian volume using the formulafor an ellipsoid (L W T 0.523). The AFCwas calculated by measuring follicles with sizes from 2 to 10 mm in both ovaries.4,15 AFC meas-urements were classiﬁed clinically as: normal when Histories of arterial thrombosis, venous thrombosis there were 10 follicles, low when there were 10 and pregnancy morbidity were detected in 17%, but >5 follicles, and very low when there were 5 83%, and 33% of the PAPS patients, respectively.
LA, aCL antibodies, and anti-b2-GPI antibodieswere detected in 67%, 83% and 11% of the PAPS Detection of anti-corpus luteum (anti-CoL) and patients, respectively. All PAPS patients were nega- other autoantibodies tive for anti-dsDNA, anti-Sm, anti-RNP, anti-Ro/SS-A and anti-La/SS-B autoantibodies.
The presence of autoantibodies directed toward a The demographic features, gynecologic history, 67 kDa protein in the corpus luteum was deter- OR test results, and anti-CoL statuses of the PAPS mined in the patient and control samples using patients and controls are depicted in Table 1. The mean age was similar between the PAPS group and Brieﬂy, crude tissue and cell extracts obtained controls (33.0 5.0 vs. 30.4 7.0 years; p ¼ 0.189).
from bovine corpus luteum (100 mg/well) were sub- The BMI, smoking status and the remaining demo- mitted to polyacrylamide gel electrophoresis under graphic features were similar in both groups denaturing and reducing conditions (with sodium (p > 0.05). The history of deliveries was superior dodecyl sulfate and b2-mercaptoethanol). Proteins in PAPS patients when compared to controls (1 were then electrophoretically transferred to a nitro- (0–6) vs. 0 (0–2), p ¼ 0.02), and there were fewer cellulose membrane. The membrane strips were fur- pregnancies per woman in the PAPS group than ther incubated with blocking buﬀer (5% skimmed in the controls (17% vs. 54%, p ¼ 0.02).
milk in phosphate-buﬀered saline (PBS)) and The frequencies of low and very low AFC were immunoprobed by incubation with serum samples greater in PAPS patients than in controls (low diluted 1:10. Reactivity was tagged with an anti- AFC: 56% vs. 22%, p ¼ 0.042; very low AFC: human immunoglobulin (Ig)G alkaline phosphat- 37% vs. 9%, p ¼ 0.045). Reduced, low and negli- ase conjugate and visualized using appropriate gible AMH levels were observed in PAPS patients more often than in controls (p Lupus anticoagulant (LA) was detected accord- ¼ 0.08, p ¼ 0.07 and ing to the guidelines of the International Society on ¼ 0.07, respectively). Serum FSH, LH and estra- Thrombosis and Hemostasis.17 Presence of anticar- diol levels were similar in PAPS patients and con- diolipin (aCL) antibodies and anti-b2-glycoprotein trols (p > 0.05). The occurrence of anti-CoL I (anti-b2-GPI) IgG and IgM were analyzed by antibodies was observed in two PAPS patients ELISA.18 The presence of additional autoantibo- (11%) and no controls (0%) (p ¼ 0.177), and one dies, including anti-double-stranded DNA (anti- of these PAPS patients had reduced OR (Table 1).
Crithidia luciliaea substrate), anti-ribonucleopro-tein (anti-RNP), anti-Sm proteins (hemagglutin- ation assay with rabbit thymus extract), anti-Ro/SS-A and anti-La/SS-B (counterimmunoelectro- To our knowledge, this is the ﬁrst study to indicate phoresis using human spleen extract as antigen) that more than half of women suﬀering from PAPS were detected.
have diminished OR. The main strength of this Ovarian reserve in PAPSLYS Yamakami et al.
Demographic features, gynecologic history, ovarian Follicle atresia, apoptosis, the location of primor- reserve tests, and anti-corpus luteum antibody (anti-CoL) in dial follicles near the granulosa cell layer, and ovar- primary antiphospholipid syndrome (PAPS) patients and ian blood supply could make primordial follicle cohorts more susceptible to microvascular ischemia events. Furthermore, diminished serum AMHlevels might be brought about by insults to the Demographic features ovarian microvasculature. A parallel dysfunction Current age, years could be drawn in male PAPS and SLE-related antiphospholipid patients, in whom morphofunc- tional penile alterations were observed.24,25 Diminished OR was most likely not related to Socioeconomic class C or D Gynecologic history Furthermore, unlike patients with other auto- Age at menarche, years immune diseases, our patients did not use immuno- Time between menarche and current age, years suppressive agents, such as cyclophosphamide26–29 or glucocorticosteroids,30 that could result in OR evaluation in patients with chronic auto- immune diseases may be inﬂuenced by age, throm- contraceptives, genetics and environmental factors such as smoking.26,27,29,31 Previous use of medrox- yprogesterone acetate, an option of contraception for women with positive aCL and/or LA,32 was not a relevant factor for this analysis since the drug was discontinued for at least six months and menstrual cycle had to be resumed. Additionally, patients and Mean ovarian volume, mm3a controls had comparable ages and very low tobacco smoking habits, which negates these factors as a Values expressed in mean standard deviation, median (range) or n causes of low OR. Additionally, none of our (%). PAPS: primary antiphospholipid syndrome; BMI: body mass patients had clinical evidence of ovarian throm- index; FSH: follicle-stimulating hormone; LH: luteinizing hormone; bosis, which is in accordance with the ﬁndings AMH: anti-Mu¨llerian hormone; AFC: antral follicle count. an ¼ 16PAPS patients and 23 controls.
described for PAPS patients.33 Regarding OR evaluation, basal serum FSH, although widely available, has been demonstrated research was the evaluation of most reliable OR to have low accuracy in diagnosis of diminished markers, including AFC and serum AMH, which OR, especially at early stages, the most important were obtained at the early follicular phase to avoid phase to be identiﬁed.27 Today, AMH and AFC are intramenstrual cycle variations in AMH levels.19,20 the best non-dynamic tests to predict ovarian per- We used strict criteria to deﬁne PAPS. Moreover, formance in human reproductive treatment.26,28 all patients discontinued use of hormonal contra- AMH is produced by granulosa cells of early- ceptives for at least six months and had resumed stage follicles and has the advantage of being two or more consecutive menstrual cycles, suggest- FSH independent, which makes its level relatively ing that ovarian function was reestablished. These stable during all menstrual cycles, and it can be precautions were taken to obtain consistent OR used in early evaluation.26 AMH assessment was evaluations because it is known that AMH concen- ﬁrst performed in SLE patients31 and it is con- trations decrease during hormonal contraceptive sidered a reliable ovarian marker.
use.21–23 However, the main limitation of this It is unlikely that autoimmunity inﬂuenced the study is the low sample size, which, in part, is low OR observed herein, which contrasts with our accounted for by the strict deﬁnition of PAPS and female SLE patients who showed an association the low incidence of this illness.
between anti-CoL antibodies and ovarian dysfunc- Low OR, as indicated by a signiﬁcant reduction tion.16 Antibodies directed to pre-ovulatory follicle in AFC, implies that primordial follicle cohort cells and not to corpus luteum-speciﬁc antigens growth may suﬀer insults within an antiphospholi- may have an impact on OR in PAPS patient. This pid milieu that manifest as a reduced follicle cohort.
ﬁeld of study deserves further research.
Ovarian reserve in PAPS LYS Yamakami et al.
The presence of a relatively high parity among 6 La Marca A, Brozzetti A, Sighinolfi G, Marzotti S, Volpe A, Falorni A. Primary ovarian insufficiency: Autoimmune causes.
PAPS patients is conceivably due to the fear of Curr Opin Obstet Gynecol 2010; 22: 277–282.
childlessness in these women and to their high preg- 7 Atabekog˘lu C, Tas¸kin S, Kahraman K, et al. The effect of total nancy morbidities.1 The elevated number of child- abdominal hysterectomy on serum anti-Mu¨llerian hormone levels:A pilot study. Climacteric 2012; 15: 393–397.
less women in the control group may reﬂect an 8 Hehenkamp WJ, Volkers NA, Broekmans FJ, et al. Loss of ovar- unanticipated selection of women interested in ian reserve after uterine artery embolization: A randomized com- learning about their OR. The focus of our work parison with hysterectomy. Hum Reprod 2007; 22: 1996–2005.
9 Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho was to assess OR markers in a cross-section JF. Severe hemorrhagic corpus luteum complicating anticoagula- study. A future study evaluating OR markers for tion in antiphospholipid syndrome. Lupus 2011; 20: 523–526.
prediction of pregnancy outcomes will be required.
10 Almeida PM. Crite´rio de classe econoˆmica da Associac¸a˜o Brasileira de Anunciantes (ABA) e Associac¸a˜o Brasileira dos In conclusion, the present report identiﬁes a high Institutos de Pesquisa de Mercado (ABIPEME). In: Almeida prevalence of diminished OR in PAPS patients.
Further studies are necessary to uncover the mech- ABIPEME. ABA/ABIPEME: Sa˜o Paulo, 1991, pp.1–29.
11 Kahapola Arachchige KM, Wardrop R, Lim EM, Stuckey B, anisms by which PAPS causes ovarian impairment.
Hadlow N. Waiting for an elevated FSH—too late a marker ofreduced ovarian reserve? Aust N Z J Obstet Gynaecol 2012; 52:460–464.
12 Esposito MA, Coutifaris C, Barnhart KT. A moderately elevated day 3 FSH concentration has limited predictive value, especially inyounger women. Hum Reprod 2002; 17: 118–123.
This work was supported by grants from Fundac¸a˜o 13 Gleicher N, Weghofer A, Barad DH. Anti-Mu¨llerian hormone (AMH) defines, independent of age, low versus good live-birth de Amparo a Pesquisa do Estado de Sa˜o Paulo chances in women with severely diminished ovarian reserve.
Fertil Steril 2010; 94: 2824–2827.
14 Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine- prospective, comparative Tecnolo´gico (CNPQ 301411/2009-3 to EB and Mu¨llerian hormone, inhibin-B, and three-dimensional ultrasound 302724/2011-7 to CAS), Federico Foundation (to determinants of ovarian reserve in the prediction of poor response EB and CAS), and Nu´cleo de Apoio a Pesquisa to controlled ovarian stimulation. Fertil Steril 2010; 93: 855–864.
15 Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ.
‘‘Sau´de da Crianc¸a e do Adolescente'' da USP Ultrasonography as a tool for the prediction of outcome in IVF (NAP-CriAd) to CAS.
patients: A comparative meta-analysis of ovarian volume andantral follicle count. Fertil Steril 2007; 87: 764–775.
16 Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E.
Anti-corpus luteum antibody: A novel serological marker for ovar- Conflict of interest statement ian dysfunction in systemic lupus erythematosus? J Rheumatol1999; 26: 1087–1093.
17 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diag- The authors have no conﬂicts of interest to declare.
nosis of lupus anticoagulants: An update. On behalf of theSubcommittee Antibody of the Scientific and Standardisation Committee of theISTH. Thromb Haemost 1995; 74: 1185–1190.
Anticardiolipin antibodies: Isotype distribution and phospholipid The authors express our gratitude to Vilma S.T.
specificity. Ann Rheum Dis 1987; 46: 1–6.
19 Cook CL, Siow Y, Taylor S, Fallat ME. Serum mu¨llerian-inhibit- Viana and Sandra G. Pasoto for technical support, ing substance levels during normal menstrual cycles. Fertil Steril and Ulysses Doria-Filho for the statistical analysis.
2000; 73: 859–861.
20 Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkha¨user MH. Statistically significant changes of antimu¨llerian hormoneand inhibin levels during the physiologic menstrual cycle in repro- ductive age women. Fertil Steril 2008; 89: 927–933.
21 Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimu¨llerian hormone levels decrease in women 1 Wilson WA, Gharavi AE, Koike T, et al. International consensus using combined contraception independently of administration statement on preliminary classification criteria for definite antipho- route. Fertil Steril 2013; 99: 1305–1310.
spholipid syndrome: Report of an international workshop. Arthritis 22 Kristensen SL, Ramlau-Hansen CH, Andersen CY, et al. The asso- Rheum 1999; 42: 1309–1311.
ciation between circulating levels of antimu¨llerian hormone and 2 Lim W, Crowther MA. Antiphospholipid antibodies: A critical follicle number, androgens, and menstrual cycle characteristics in review of the literature. Curr Opin Hematol 2007; 14: 494–499.
young women. Fertil Steril 2012; 97: 779–785.
3 Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms 23 Arbo E, Vetori DV, Jimenez MF, Freitas FM, Lemos N, Cunha- and clinical consequences. Endocr Rev 2009; 30: 465–493.
Filho JS. Serum anti-mullerian hormone levels and follicular 4 The Practice Committee of the American Society for Reproductive cohort characteristics after pituitary suppression in the late luteal Medicine. Testing and interpreting measures of ovarian reserve: A phase with oral contraceptive pills. Hum Reprod 2007; 22: committee opinion. Fertil Steril 2012; 98: 1407–1415.
5 Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis 24 Rabelo-Ju´nior CN, Freire de Carvalho J, Lopes Gallinaro A, et al.
as a mechanism of follicular dysfunction in women with 46,XX Primary antiphospholipid syndrome: Morphofunctional penile spontaneous premature ovarian failure. Fertil Steril 2005; 84: abnormalities with normal sperm analysis. Lupus 2012; 21: Ovarian reserve in PAPSLYS Yamakami et al.
25 Rabelo-Ju´nior CN, Bonfa´ E, Carvalho JF, et al. Penile alterations 29 Aikawa NE, Sallum AM, Leal MM, Bonfa´ E, Pereira RM, Silva with severe sperm abnormalities in antiphospholipid syndrome CA. Menstrual and hormonal alterations in juvenile dermatomyo- associated with systemic lupus erythematosus. Clin Rheumatol sitis. Clin Exp Rheumatol 2010; 28: 571–575.
2013; 32: 109–113.
30 Silva CA, Deen ME, Febroˆnio MV, et al. Hormone profile in 26 Silva CA, Bonfa E, Østensen M. Maintenance of fertility in juvenile systemic lupus erythematosus with previous or current patients with rheumatic diseases needing antiinflammatory and amenorrhea. Rheumatol Int 2011; 31: 1037–1043.
immunosuppressive drugs. Arthritis Care Res (Hoboken) 2010; 31 Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus 62: 1682–1690.
erythematosus on ovarian reserve in premenopausal women: 27 Silva CA, Brunner HI. Gonadal functioning and preservation of Evaluation by using anti-Muellerian hormone. Lupus 2011; 20: reproductive fitness with juvenile systemic lupus erythematosus.
Lupus 2007; 16: 593–599.
32 Lateef A, Petri M. Hormone replacement and contraceptive ther- 28 Aikawa NE, Sallum AM, Pereira RM, et al. Subclinical impair- apy in autoimmune diseases. J Autoimmun 2012; 38: J170–J276.
ment of ovarian reserve in juvenile systemic lupus erythematosus 33 Andre´ M, Dele vaux I, Amoura Z, et al. Ovarian vein thrombosis in after cyclophosphamide therapy. Clin Exp Rheumatol 2012; 30: the antiphospholipid syndrome. Arthritis Rheum 2004; 50:
TÉRMINOS Y CONDICIONES DE COMPRA DE VALEO VALEO PURCHASING TERMS AND CONDITIONS Índice / Table of Contents Oferta; Aceptación, Términos Exclusivos / Offer; Acceptance; Exclusive Terms……………………………………. Cantidad y Vigencia / Quantity and Duration ………………………………………………………………………….